Xiaodong Wang sold $2.1M of ONC
director, other at BeOne Medicines Ltd.. 8,146 shares at an average of $254.58, traded Mar 4, 2025, filed Mar 6, 2025.
Score components
- +15RoleDirector
- +25Trade size$2.1M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster6 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001651308-25-000042, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 4, 2025 | SOpen-market sale American Depositary Sharesindirect: See Footnote10b5-1 | -700 | $251.70 | $176k | 7,446 | Mar 6, 2025 |
| Mar 4, 2025 | SOpen-market sale American Depositary Sharesindirect: See Footnote10b5-1 | -2,000 | $252.72 | $505k | 5,446 | Mar 6, 2025 |
| Mar 4, 2025 | SOpen-market sale American Depositary Sharesindirect: See Footnote10b5-1 | -825 | $253.55 | $209k | 4,621 | Mar 6, 2025 |
| Mar 4, 2025 | SOpen-market sale American Depositary Sharesindirect: See Footnote10b5-1 | -1,275 | $254.77 | $325k | 3,346 | Mar 6, 2025 |
| Mar 4, 2025 | SOpen-market sale American Depositary Sharesindirect: See Footnote10b5-1 | -1,214 | $255.71 | $310k | 2,132 | Mar 6, 2025 |
| Mar 4, 2025 | SOpen-market sale American Depositary Sharesindirect: See Footnote10b5-1 | -1,809 | $256.83 | $465k | 323 | Mar 6, 2025 |
| Mar 4, 2025 | SOpen-market sale American Depositary Sharesindirect: See Footnote10b5-1 | -323 | $257.41 | $83k | 0 | Mar 6, 2025 |
Related signals
Other insiders at BeOne Medicines Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | BeOne Medicines Ltd. | Chan Henry Lee SVP, General Counsel | $418k 1,115 shares | -100% | |
| 33Weak | BeOne Medicines Ltd. | Xiaodong Wang director, other | $11M 31,028 shares | -100% | |
| 33Weak | BeOne Medicines Ltd. | Xiaodong Wang director, other | $13M 38,287 shares | -527% | |
| 49Moderate | BeOne Medicines Ltd. | Titus B. Ball Principal Accounting Officer | $47k 132 shares | -100% | |
| 41Moderate | ONCsell BeOne Medicines Ltd. | Titus B. Ball Principal Accounting Officer | $35k 134 shares | -100% | |
| 40Moderate | BeOne Medicines Ltd. | Xiaodong Wang director, other | $11M 41,760 shares | -100% | |
| 70Notable | BeOne Medicines Ltd. | John Oyler Chief Executive Officer | $10M 41,210 shares | -100% | |
| 45Moderate | BeOne Medicines Ltd. | Xiaobin Wu President, COO & GM China | $14M 51,921 shares | -100% | |
| 70Notable | BeOne Medicines Ltd. | John Oyler Chief Executive Officer | $10M 40,109 shares | -100% | |
| 70Notable | BeOne Medicines Ltd. | John Oyler Chief Executive Officer | $15M 58,590 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.